港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍公司已达成多项重磅对外授权

智通财经02-03

智通财经APP获悉，百奥赛图-B(02315)再涨超10%，截至发稿，涨8.58%，报45.56港元，成交额6619.52万港元。消息面上，百奥赛图近期发布2025年度业绩预告，预期归母净利润1.62亿元至1.82亿元，同比增加384.26%到443.88%。公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位，精益化管理...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608481958?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-03 11:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608481958","market":"hk","top_or_hot":-1,"title":"港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，百奥赛图-B(02315)再涨超10%，截至发稿，涨8.58%，报45.56港元，成交额6619.52万港元。消息面上，百奥赛图近期发布2025年度业绩预告，预期归母净利润1.62亿元至1.82亿元，同比增加384.26%到443.88%。公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位，精益化管理...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1400891.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-03 11:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1400891.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，百奥赛图-B(02315)再涨超10%，截至发稿，涨8.58%，报45.56港元，成交额6619.52万港元。消息面上，百奥赛图近期发布2025年度业绩预告，预期归母净利润1.62亿元至1.82亿元，同比增加384.26%到443.88%。公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位，精益化管理...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1400891.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VT","symbol_name":"世界全股市ETF-Vanguard","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1400891.html","article_id":"2608481958","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608481958","pubTimestamp":1770087766,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，百奥赛图-B再涨超10%，截至发稿，涨8.58%，报45.56港元，成交额6619.52万港元。消息面上，百奥赛图近期发布2025年度业绩预告，预期归母净利润1.62亿元至1.82亿元，同比增加384.26%到443.88%。公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水平得以快速提高。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688796":"百奥赛图","VT":"世界全股市ETF-Vanguard","BK0216":"研究试验","02315":"百奥赛图-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技"},"translate_title":"Changes in Hong Kong stocks | Biocyto-B (02315) rose by more than 10% again, and the full-year net profit is expected to increase by up to 4.4 times. The company has reached a number of major external authorizations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1.5,"VT":1.5,"02315":1.5},"content_text":"智通财经APP获悉，百奥赛图-B(02315)再涨超10%，截至发稿，涨8.58%，报45.56港元，成交额6619.52万港元。消息面上，百奥赛图近期发布2025年度业绩预告，预期归母净利润1.62亿元至1.82亿元，同比增加384.26%到443.88%。公告称，受益于海外市场的持续拓展，叠加国内生物医药行业的复苏回暖，公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位，精益化管理举措进一步推动运营效率提升，公司盈利水平得以快速提高。国联民生证券表示，2025年以来，公司与多家国内外头部药企达成对外授权，并有多条管线获得IND批准，随着授权管线的推进，公司有望获得里程碑付款等收入，进一步打开增长天花板，对外授权包括：2025年7月，公司与百济神州达成抗体分子的全球许可协议，百济神州在全人抗体平台的授权基础上将合作拓展至抗体分子授权许可领域；2025年9月，公司与默克达成RenMice平台自主开发的全人抗体的授权，将用于开发抗体偶联LNP。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608481958","isCrawlerRequest":true}

港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权

精彩评论

港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍公司已达成多项重磅对外授权